Translate Bio Inc
NASDAQ:TBIO 3:59:56 PM EDT
| Market Cap (Intraday) | 1.68B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $22.39 |
| 50-Day MA | $20.74 |
| 200-Day MA | $16.58 |
Translate Bio, Inc. Stock, NASDAQ:TBIO
29 HARTWELL AVENUE, LEXINGTON, MA 02421
United States of America
Phone: 617-945-7361
Number of Employees: 81
Description
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens, as well as against COVID-19. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.